Quick Answer
Quince Therapeutics, Inc. reported R&D Expense of $18.59 million for fiscal year 2024.
Quince Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2024 | $18.59M | +96.8% |
| 2023 | $9.45M | -62.5% |
| 2022 | $25.18M | -58.6% |
| 2021 | $60.80M | -0.8% |
| 2020 | $61.31M | +102.9% |
| 2019 | $30.21M | +199.6% |
| 2018 | $10.09M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $8.08M | +64.4% | +23.3% |
| June 30, 2025 | $6.55M | +58.0% | -19.5% |
| March 31, 2025 | $8.14M | +120.0% | +65.7% |
| September 30, 2024 | $4.92M | +243.5% | +18.5% |
| June 30, 2024 | $4.15M | +206.5% | +12.0% |
| March 31, 2024 | $3.70M | +14.6% | +158.7% |
| September 30, 2023 | $1.43M | -41.6% | +5.8% |
| June 30, 2023 | $1.35M | -81.2% | -58.1% |
- Quince Therapeutics, Inc. showed an increase of +96.8% in R&D Expense compared to the prior fiscal year.
- Over the 2018–2024 period, Quince Therapeutics, Inc.’s r&d expense has grown by 84.3% (from $10.09 million to $18.59 million).
- The most recent figure is from Quince Therapeutics, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 24, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: